BAFFR X CD3 BI-SPECIFIC ANTIBODIES AND METHODS OF USE

Claims

The present invention relates to antibodies that bind specifically to human BAFFR, to bispecific antibodies that bind specifically to both human BAFFR and human CD3, compositions comprising such antibodies, and methods of using the same.

1. A bispecific antibody that specifically binds to the human B-cell activating factor receptor (hBAFFR) and human CD3 (hCD3), wherein the bispecific antibody comprises (a) a first antigen-binding domain that specifically binds to hBAFFR comprising a first heavy chain variable region (VH1) and a light chain variable region (VL1), wherein VH1 comprises heavy chain complementarity-determining regions (HCDRs) HCDR1, HCDR2, and HCDR3, and VL1 comprises light chain complementarity-determining regions (LCDRs) LCDR1, LCDR2, and LCDR3, wherein: (a) HCDR1 comprises sec. with ident. no. 1, HCDR2 comprises sec. with ident. no. 2, HCDR3 comprises sec. with ident. no. 3, and HCDR4 comprises sec. with ident. no.

4. ID: 3, LCDR1 comprises sec. with number ID: 4, LCDR2 comprises sec. with number ID: 5, LCDR3 includes sec. with number ID: 6; or (b) HCDR1 comprises sec. with number of id.: 29, HCDR2 comprises sec. with number ID: 30, HCDR3 includes sec. with number ID: 31, LCDR1 comprises sec. with number ID: 4, LCDR2 comprises sec. with number ID: 5, LCDR3 includes sec. with number ID:

6. and a second antigen binding domain that specifically binds to human CD3. .

22. A process for producing a bispecific antibody comprising growing the cell of claim 20 or 21 in a culture medium under conditions such that the bispecific antibody is expressed and then recovered from the culture medium.

52. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1-17 and 23 or the antibody of any one of claims 24-32 or the ADC of claims 33-34 or the immunocytokine of claims 35-36 or the CAR of claim 37 for use in the treatment of an autoimmune disorder.